4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride

Request For Quotation
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Suppliers list
Company Name: TargetMol Chemicals Inc.  Gold
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  Gold
Tel: 021-52996696，15000506266 15000506266
Email:
Company Name: CHANGZHOU PHARMACEUTICAL FACTORY  Gold
Tel: 0519-88821493 18915891730
Email: shm@czpharma.com
Company Name: Wuhan Jingkangen Biomedical Technology Co., Ltd  Gold
Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com

4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride manufacturers
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Basic information
Product Name:4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride
Synonyms:4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride;EOS-61917;LNP023 hcl;LNP023 hydrochloride;Iptacopan(lnp023);Iptacopanhydrochloride;Iptacopanhydrochloride，LNP023 hcl;Iptacopan HCl
CAS:1646321-63-2
MF:C25H31ClN2O4
MW:458.98
EINECS:
Product Categories:
Mol File:1646321-63-2.mol
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Structure
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Chemical Properties
storage temp. Store at -20°C
solubility DMSO : 250 mg/mL (544.69 mM; Need ultrasonic)|
form A solid
color White to off-white
Water Solubility Water : 50 mg/mL (108.94 mM; ultrasonic and warming and heat to 60°C)
InChIKeySEZXOFFLNHXEJE-QHWHZDSMNA-N
SMILESC(N1CC[C@H](OCC)C[C@H]1C1C=CC(C(=O)O)=CC=1)C1C(=CC(C)=C2NC=CC=12)OC.Cl |&1:4,9,r|
Safety Information
MSDS Information
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Usage And Synthesis
UsesLNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 inhibits factor B with an IC50 value of 10 nM[1][2].
in vivo

LNP023 (20-180 mg/kg; oral administration) prevents KRN (150 μL)-induced arthritis in mice and is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats[2].
LNP023 exhibits moderate half-lives (T1/2; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and Cmax (Wistar Han rats 410 nM, beagle dogs 2200 nM) following oral administration (rat 30 and, dog 10 mg/kg)[3].
LNP023 exhibits terminal elimination half-lives (T1/2; Wistar Han rats 7 h, beagle dogs 5.6 h) due to high plasma clearance (8, and 2 mL/min/kg respectively combined with large volumes of distribution (2.3, and 0.6 L/kg respectively) following intravenous administration (rat 1.0 and, dog 0.1 mg/kg)[3].

Animal Model:C57BL/6 mice with KRN-induced arthritis[2]
Dosage:20, 60, and 180 mg/kg
Administration:Orally gavaged; twice a day (b.i.d.) for 14 days
Result:Blocked KRN-induced arthritis.
References[1] Dimitrios C Mastellos, et al. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Semin Hematol. 2018 Jul;55(3):167-175. DOI:10.1053/j.seminhematol.2018.02.002
[2] Anna Schubart, et al. Small-molecule Factor B Inhibitor for the Treatment of Complement-Mediated Diseases. Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. DOI:10.1073/pnas.1820892116
[3] Nello Mainolfi, et al. Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. DOI:10.1021/acs.jmedchem.9b01870
4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Preparation Products And Raw materials
Tag:4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride(1646321-63-2) Related Product Information
Benzoic acid, 4-[(2S,4R)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]- Iptacopan Benzoic acid, 4-[(2R,4R)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]-, rel- Benzoic acid, 4-[(2R,4R)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]- 4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoicacidhydrochloride Benzoic acid, 4-[(2R,4R)-1-[(7-cyclopropyl-5-methoxy-1H-indol-4-yl)methyl]-4-ethoxy-2-piperidinyl]-, rel-